R&D Future of generative AI in pharma Talk of implementing automation and AI to enhance human capacity is dominating conversations.
Sales & Marketing Sponsored Start-ups and tech giants are the future of pharma marketing We are living in a revolutionary time of scientific change and innovation in pharma marketing – and the opportunities are tremendous.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.